Saturday 17 October 2026
Export APVO’s income statement to Excel — free account
Aptevo Therapeutics Inc.
APVO Healthcare Biotechnology
Aptevo Therapeutics Inc.’s revenue for fiscal 2022 (year ended December 2022) was $3.1 million. In the quarter to June 2026, EPS grew 96.5% and free cash flow grew 23.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.62
0.08
−4.71%
Follow APVO
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | 0.92 | 0.00 | 0.00 | 0.00 | 0.00 | 6.38 | 0.00 |
Piotroski F-Score |
— | — | — | 4 | 3 | 3 | 3 | 2 | 6 | 2 |
P/S ratio |
— | — | — | 527,133.51 | 1,759,124.90 | 5,460,128.21 | 483,499.54 | 10,164,405.30 | 56,728,401.70 | 41,578,223.25 |
Altman Z-Score |
— | — | — | 256,174.47 | 234,243.36 | 1,182,655.11 | 226,288.86 | 3,793,066.32 | 12,734,392.50 | 5,887,741.41 |
P/FCF ratio |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | — | (20.50) | (12.78) | (10.27) | (16.11) | (7.42) | 1.60 | (8.03) |
Beneish M-Score |
— | — | — | 3.69 | (2.01) | (3.75) | — | (1.47) | 1.13 | — |
P/Operating CF |
— | — | — | (1,152,522.07) | (5,572,980.22) | (11,895,820.73) | (3,073,919.44) | (32,153,364.93) | (53,921,594.71) | (62,289,356.22) |
P/B ratio |
— | — | — | 380,818.33 | 17,782,206.63 | 4,389,424.51 | 1,323,846.41 | 7,711,054.96 | 10,136,221.27 | 8,210,231.36 |
Price to Tangible BV |
— | — | — | 512,874.91 | 0.00 | 6,087,089.28 | 2,173,134.07 | 9,320,334.59 | 10,947,599.40 | 9,509,770.92 |
EV/Sales |
— | — | — | 527,132.03 | 1,759,122.38 | 5,460,126.90 | 483,499.87 | 10,164,404.99 | 56,728,397.46 | 41,578,219.60 |
EV/EBITDA |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | (325,602.20) | (997,422.96) | (2,484,415.47) | (369,888.87) | (4,559,572.36) | (20,001,559.91) | (11,262,506.72) |
EV/FCF |
— | — | — | (323,341.18) | (965,663.29) | (2,476,980.64) | (368,558.40) | (4,474,642.73) | (19,349,036.65) | (10,543,976.30) |
Quick Ratio |
3.57 | 1.40 | 2.34 | 2.89 | 1.44 | 3.09 | 0.51 | 2.04 | 4.50 | 2.83 |
Current Ratio |
3.82 | 1.72 | 2.64 | 3.15 | 1.51 | 3.25 | 0.78 | 2.76 | 5.14 | 3.65 |
Net Debt/EBITDA |
0.83 | 0.36 | 0.60 | 0.69 | 1.53 | 0.67 | (0.28) | 0.23 | 1.22 | 0.27 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 10.10% | 27.16% | 46.79% | 43.42% | 28.56% | 16.29% | 20.01% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.19 | 12.64 | 1.51 | 1.96 | 0.63 | 0.23 | 0.36 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.07 | 0.22 | 0.08 | 0.54 | 0.25 | 0.14 | 0.09 |
Operating CF/Net income |
0.93 | 0.99 | 0.67 | (2.62) | 0.76 | 1.65 | 1.05 | 0.96 | (5.96) | 0.33 |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (0.03) | (0.62) | (0.06) | (0.07) | (0.41) | (0.45) | (0.75) |
| (248.81%) | (284.28%) | (115.32%) | 83.66% | (319.56%) | (124.84%) | (191.48%) | (95.50%) | 10.52% | (161.53%) | |
| (128.73%) | (119.36%) | (58.96%) | 17.68% | (51.67%) | (33.19%) | (66.91%) | (58.20%) | 6.68% | (102.37%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (113.36%) | (169.51%) | (169.33%) | (618.46%) |
Return on Tangible Assets |
(158.87%) | (483.08%) | (136.70%) | 39.73% | (140.93%) | (49.94%) | 941.09% | (147.98%) | 8.46% | (194.56%) |
Average Days of Receivables |
— | — | — | 293.03 | 108.80 | 200.67 | 79.05 | 82.60 | 53.31 | 11.22 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 574.25% | 154.52% | 414.30% | 76.37% | 153.40% | 197.99% | 291.64% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 445.50% | 119.57% | 323.76% | 49.96% | 121.96% | 235.88% | 362.12% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 | 0.05 | 0.08 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 57.87% | 13.37% | 29.13% | 4.93% | 9.28% | 33.32% | 38.15% |
Graham Net Nets |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Graham Number |
— | — | — | 10,732.45 | 0.00 | 0.00 | 0.00 | 0.00 | 22,993.77 | 0.00 |
Earnings Yield |
— | — | — | 108.23% | (60.00%) | (3.23%) | (134.66%) | 0.00% | 15.68% | (168.17%) |
Free Cash Flow Yield |
— | — | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.61 | 2.62 | 1.27 | 11.12 | 1.03 | 0.69 | 0.49 |
Operating CF per Share |
(81.12) | (29,731.25) | 0.00 | (4.12) | (4.62) | (8.65) | (14.53) | (2.29) | (1.95) | (1.82) |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | (0.15) | (0.03) | (0.05) | (0.04) | (0.07) | (0.12) |
Free Cash Flow per Share |
(81.12) | (29,731.25) | 0.00 | (4.13) | (4.78) | (8.67) | (14.58) | (2.33) | (2.01) | (1.95) |
Cash per Share |
68.52 | 10,892.50 | 0.00 | 4.44 | 9.88 | 12.54 | 4.27 | 1.36 | 3.81 | 2.71 |
Shareholders Equity per Share |
55.09 | 5,943.75 | 0.00 | 3.52 | 0.26 | 4.89 | 4.06 | 1.35 | 3.85 | 2.50 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
55.09 | 5,943.75 | 0.00 | 3.52 | 0.26 | 4.89 | 4.06 | 1.35 | 3.85 | 2.50 |
Free Cash Flow |
(25.59) | (23.78) | (11.73) | (21.05) | (22.39) | (29.41) | (42.54) | (52.40) | (42.97) | (39.37) |
Working Capital |
17.03 | 4.45 | 11.84 | 18.74 | 17.81 | 32.73 | (8.24) | 31.08 | 76.57 | 51.87 |
Capital Expenditures |
— | — | — | (0.03) | (0.71) | (0.09) | (0.15) | (0.98) | (1.40) | (2.51) |
Net Current Asset Value |
13.27 | (0.18) | 6.45 | 11.21 | (2.81) | 10.31 | (11.57) | 11.60 | 60.11 | 30.12 |
EV/EBIT |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | — | — | 0.01 | 0.06 | 0.02 | 0.00 | 0.04 | 0.10 | 0.25 |
Price to Operating Income |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.79 | 0.65 | 0.63 | 0.62 | 0.48 | 0.50 | 0.57 | 0.46 | 0.54 | 0.57 |
Cash ROIC |
(65.62%) | (176.59%) | (40.27%) | (47.77%) | (35.60%) | (34.93%) | (89.59%) | (65.24%) | (23.58%) | (31.79%) |
Accounts Receivable Turnover |
— | — | — | 1.01 | 4.07 | 0.92 | 5.30 | 6.27 | 11.98 | 2.45 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.18 | 0.56 | 1.21 |
Inventory Turnover |
— | — | — | 0.00 | — | — | 0.00 | 7.97 | 6.73 | 1.20 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 379.87 | 535.48 | 307.94 |
Days of Inventory on Hand |
— | — | — | 0.00 | — | — | 1,002.57 | 58.10 | 74.89 | 13.50 |
Average Receivables |
— | — | — | 3.08 | 3.02 | 4.70 | 6.12 | 3.68 | 1.22 | 4.07 |
Average Payables |
1.06 | 2.61 | 3.74 | 3.48 | 4.52 | 6.01 | 9.05 | 9.51 | 8.93 | 10.30 |
Average Inventory |
— | — | — | — | — | — | 3.96 | 1.41 | 0.74 | 10.39 |
Average Assets |
21.39 | 20.22 | 29.53 | 45.41 | 55.07 | 53.48 | 60.45 | 92.25 | 104.43 | 109.81 |
Average Common Equity |
11.07 | 8.49 | 15.10 | 9.60 | 8.91 | 14.22 | 21.12 | 56.22 | 66.30 | 69.59 |
Columns are period end dates